Anavex Life Sciences Corp.

符号: AVXL

NASDAQ

3.85

USD

今天的市场价格

-7.3224
市盈率
-2.2699
PEG比率
311.23M
MRK市值
0.00%
DIV收益率

Anavex Life Sciences Corp. (AVXL) 财务报表

Q: 什么是 Anavex Life Sciences Corp. (AVXL) 总资产是多少？

Anavex Life Sciences Corp. (AVXL) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Anavex Life Sciences Corp. (AVXL). 的默认数据。公司收入显示 0 M 的平均值，即 0.000 % 增长率。整个期间的平均毛利润为 -0.012 M，即 -4.629 %. 平均毛利率为 0.000 %. 公司去年的净收入增长率为 -0.010 %，等于 -3.586 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Anavex Life Sciences Corp. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 0.011. 在流动资产领域，AVXL 的报告货币为154.386. 这些资产中的很大一部分，即 151.024 是现金和短期投资。与去年的数据相比，该部分的变化率为0.013%. 公司的长期投资虽然不是其重点，但以报告货币计算的0（如果有的话）为0。这表明与上一报告期相比，0.000% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 0. 这一数字表明，0.000% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 141.852. 这方面的年同比变化率为 -0.004%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为2.709，存货估值为 0，商誉估值为 0（如有. 无形资产总额（如果有）按 0 估值.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004
balance-sheet.row.cash-and-short-term-investments	603.07	151	149.2	152.1	29.2	22.2	22.9	27.4	9.2	15.3	7.3	0.3	0	0.1	0.3	0.4	0	0	0	0	0
balance-sheet.row.short-term-investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	13.16	2.7	3.2	9.1	4.8	2.6	0	0	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.inventory	0	0	0	0	0	-2.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-current-assets	3.22	0.7	0.4	0.4	0.4	3.1	1.4	0.3	0.2	0.1	0.1	0	0	0.1	0	0.1	0	0	0	0	0
balance-sheet.row.total-current-assets	619.45	154.4	152.7	161.6	34.5	25.3	24.3	27.8	9.4	15.5	7.4	0.4	0	0.2	0.3	0.4	0	0	0	0	0
balance-sheet.row.property-plant-equipment-net	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	3.36	0	0	0	0	0	0.1	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-non-current-assets	3.36	0	0	0	0	0	0.1	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-assets	8713.08	3.4	3546.7	0	5.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	619.45	154.4	152.7	161.6	34.5	25.3	24.4	27.8	9.5	15.5	7.4	0.4	0	0.2	0.3	0.4	0	0	0	0	0
balance-sheet.row.account-payables	19.05	4.3	3.8	4.7	4	3.5	0	0	0	0	0	0	0	0.4	0	1.6	0.7	0.5	0	0	0
balance-sheet.row.short-term-debt	0	0	0	0	0	0	0	0	0	0.1	0.2	0.2	0.3	0.9	2.5	2.5	1.6	0	0	0	0
balance-sheet.row.tax-payables	0	0	0	0	0	0	0	0	-14.7	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	0	0	0	0	0	0	0	0	0	0	5.7	0	0	0	0	0	0	0	0	0	0
Deferred Revenue Non Current	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	27.39	7.3	5.9	5.6	3.3	1.5	3.9	3.6	3.1	2.5	1.2	1.7	2.6	0.1	0.8	4.1	2.3	0	0	0	0
balance-sheet.row.total-non-current-liabilities	12823.08	7.3	4.3	5.6	3.3	1.5	0	0	0	0	5.7	0.9	0	0	0	0.2	0	0	0	0	0
balance-sheet.row.other-liabilities	-12823.08	-7.3	-4.3	-5.6	-3.3	-1.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	50.11	12.5	10.2	10.8	7.3	5	3.9	3.6	3.2	2.7	7.2	2.9	2.9	1.3	3.3	4.3	2.3	0.5	0	0	0
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	0.33	0.1	0.1	0.1	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-1149.33	-293.1	-245.6	-197.6	-159.7	-133.4	-108.9	-91.5	-78	-63.3	-52.6	-41.2	-37.5	-29.2	-21.9	-12.6	-7.1	-1.7	-0.1	-0.1	0
balance-sheet.row.accumulated-other-comprehensive-income-loss	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	1718.35	434.8	388	348.3	186.9	153.6	129.4	115.7	84.3	76.1	52.7	38.7	34.6	28	18.9	8.7	4.6	1.2	0.1	0.1	0
balance-sheet.row.total-stockholders-equity	569.35	141.9	142.5	150.8	27.2	20.3	20.5	24.3	6.3	12.8	0.2	-2.5	-2.9	-1.1	-3	-3.9	-2.3	-0.5	0	0	0
balance-sheet.row.total-liabilities-and-stockholders-equity	619.45	154.4	152.7	161.6	34.5	25.3	24.4	27.8	9.5	15.5	7.4	0.4	0	0.2	0.3	0.4	0	0	0	0	0
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	569.35	141.9	142.5	150.8	27.2	20.3	20.5	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	619.45	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-debt	0	0	0	0	0	0	0	0	0	0.1	5.9	0.2	0.3	0.9	2.5	2.5	1.6	0	0	0	0
balance-sheet.row.net-debt	-603.07	-151	-149.2	-152.1	-29.2	-22.2	-22.9	-27.4	-9.2	-15.2	-1.4	-0.1	0.3	0.7	2.2	2.2	1.5	0	0	0	0

现金流量表

在 Anavex Life Sciences Corp. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 -0.146 的转变。该公司最近通过发行 27.88 扩大了股本，与上一年相比出现了5.204 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 0.5. 公司的投资活动产生了现金使用净额，按报告货币计算达到0.000. 与上一年相比， 0.000 发生了变化. 在同一时期，公司记录了 0, 0 和 0，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 1.78，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004
cash-flows.row.net-income	-43.16	-47.5	-48	-37.9	-26.3	-26.3	-17.5	-13.5	-14.7	-12.1	-11.4	-3.7	-8.3	-7.3	-8.8	-5.5	-5.4	-1.6	-0.1
cash-flows.row.depreciation-and-amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.deferred-income-tax	0	0	0	0	0	0	0	0	-0.1	0.5	5.6	0.5	3.9	8.4	0.5	0.8	-1.7	0	0
cash-flows.row.stock-based-compensation	13.31	16.4	18.4	8.2	4.9	6.4	5.5	4.1	5.1	1.6	0.6	1	0.3	1.3	0.8	0.8	1.7	0	0
cash-flows.row.change-in-working-capital	-0.31	2.5	5.4	-0.7	0.1	1.3	-0.6	0.4	0.6	1.2	-0.3	0.5	2.3	1.2	-0.1	0.9	0.5	0.5	0
cash-flows.row.account-receivables	0.55	0.5	5.9	-4.3	-2.2	-0.8	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-1.53	-0.5	-5.9	4.3	2.2	0.8	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.account-payables	-1	0.5	-0.9	0.8	0.5	0.7	0	0	-151.4	0	0	1	2.3	0.3	0.4	0.9	0.5	0	0
cash-flows.row.other-working-capital	1.67	2	6.3	-1.5	-0.3	0.6	-0.6	0.4	152	1.2	-0.3	-0.5	0	0.8	-0.5	0	0	0.5	0
cash-flows.row.other-non-cash-items	0.84	0.8	0	0	0	0	0	-0.1	-0.1	4.5	2.8	1	0.1	-7.3	3	0.2	2.4	0.8	0
cash-flows.row.net-cash-provided-by-operating-activities	-29.31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.acquisitions-net	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.sales-maturities-of-investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-investing-activites	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.debt-repayment	0	0	0	0	0	0	0	0	0	-0.1	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-issued	27.93	27.9	21	153.2	28.8	17.8	8.2	27.3	3.2	12.3	0.4	0.8	1	0	3.1	1.6	1.1	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-financing-activites	1.52	1.8	0.3	0	-0.4	-0.1	-0.1	0	0	0	9.2	0.3	0.6	3.7	1.4	1.5	1.4	0.3	0
cash-flows.row.net-cash-used-provided-by-financing-activities	29.45	29.7	21.3	153.2	28.4	17.8	8.1	27.3	3.1	12.3	9.6	1.1	1.6	3.7	4.5	3.1	2.5	0.3	0
cash-flows.row.effect-of-forex-changes-on-cash	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	0.14	1.9	-2.9	122.9	7.1	-0.7	-4.5	18.3	-6.1	8	6.9	0.3	-0.1	-0.1	-0.1	0.3	0	0	0
cash-flows.row.cash-at-end-of-period	603.07	151	149.2	152.1	29.2	22.2	22.9	27.4	9.2	15.3	7.3	0.3	0	0.1	0.3	0.4	0	0	0
cash-flows.row.cash-at-beginning-of-period	602.93	149.2	152.1	29.2	22.2	22.9	27.4	9.2	15.3	7.3	0.3	0	0.1	0.3	0.4	0	0	0	0
cash-flows.row.operating-cash-flow	-29.31	-27.8	-24.2	-30.4	-21.3	-18.5	-12.6	-9	-9.2	-4.2	-2.7	-0.8	-1.7	-3.8	-4.6	-2.8	-2.5	-0.3	-0.1
cash-flows.row.capital-expenditure	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.free-cash-flow	-29.31	-27.8	-24.2	-30.4	-21.3	-18.5	-12.6	-9	-9.2	-4.2	-2.7	-0.8	-1.7	-3.8	-4.6	-2.8	-2.5	-0.3	-0.1

利润表行

Anavex Life Sciences Corp. 的收入与上期相比变化了 0.000%。据报告, AVXL 的毛利润为 0。该公司的营业费用为 55.76，与上年相比变化了 9.356%. 折旧和摊销费用为 0，与上一会计期间相比变化了 0.000%. 营业费用报告为 55.76，显示9.356% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长0.127%. 营业收入为 -47.5，与上年相比变化了-0.127%. 净利润的变化率为 -0.010%。去年的净收入为-47.49.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004
income-statement-row.row.total-revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.cost-of-revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0.1	0	0	0
income-statement-row.row.gross-profit	0	0	0	0	0	0	0	0	0	0	0	0	0	-0.1	0	0	-0.1	-0.1	0	0	0
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	40.33	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	11.33	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	2.58	2.7	3.3	-0.1	-0.1	-0.3	1.6	2	0.2	0	0.2	-1	0	0	0	0	0	0	0	0	0
income-statement-row.row.operating-expenses	51.67	55.8	51	41.9	30.9	28.8	19.2	15.5	14.9	7.1	3	2.1	4.3	6.2	5.6	4.7	5.3	1.6	0	0.1	0
income-statement-row.row.cost-and-expenses	51.67	55.8	51	41.9	30.9	28.8	19.2	15.5	14.9	7.1	3	2.1	4.3	6.2	5.6	4.7	5.3	1.6	0	0.1	0
income-statement-row.row.interest-income	7.26	6.5	0.9	0	0.2	0.2	0.3	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.interest-expense	-1.13	1	0.9	0	0	0.2	0	0	11.3	0.1	0	0.1	0.1	0.1	0.3	0.1	0	0	0	0	0
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	2.83	2.7	6.8	4.3	4.5	2.5	1.6	2.1	0.2	0.1	0.2	-1.5	-3.8	-1	-2.8	-0.7	0	0	0	0	0
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	2.58	2.7	3.3	-0.1	-0.1	-0.3	1.6	2	0.2	0	0.2	-1	0	0	0	0	0	0	0	0	0
income-statement-row.row.total-operating-expenses	2.83	2.7	6.8	4.3	4.5	2.5	1.6	2.1	0.2	0.1	0.2	-1.5	-3.8	-1	-2.8	-0.7	0	0	0	0	0
income-statement-row.row.interest-expense	-1.13	1	0.9	0	0	0.2	0	0	11.3	0.1	0	0.1	0.1	0.1	0.3	0.1	0	0	0	0	0
income-statement-row.row.depreciation-and-amortization	2.23	0	4.3	0.2	-0.3	-0.1	1.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.ebitda-caps	-46.68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-48.91	-47.5	-54.4	-41.9	-30.8	-28.8	-19.2	-15.5	-14.9	-7.1	-3	-2.1	-4.3	-6.2	-5.6	-4.7	-5.3	-1.6	0	-0.1	0
income-statement-row.row.income-before-tax	-43.04	-47.5	-47.6	-37.6	-26.3	-26.2	-17.4	-13.4	-14.7	-12.1	-11.4	-3.7	-8.2	-7.2	-8.5	-5.4	-5.3	-1.6	0	-0.1	0
income-statement-row.row.income-tax-expense	0.11	0	0.4	0.3	0	0.1	0.1	0.1	0	0.1	0	0.1	4	1.1	3.1	0.8	0.1	0	0	0	0
income-statement-row.row.net-income	-43.16	-47.5	-48	-37.9	-26.3	-26.3	-17.5	-13.5	-14.7	-12.1	-11.4	-3.7	-8.3	-7.3	-8.8	-5.5	-5.4	-1.6	0	-0.1	0